NCT03309111 - Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

BIOLOGICAL

ISB 1342

ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)

Trial Locations (20)

10029

Mount Sinai Beth Israel, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

13009

L'Institut Paoli - Calmettes, Marseille

21287

Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore

33604

CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque, Pessac

35033

CHU de Rennes - Hôpital Pontchaillou, Rennes

37044

CHRU de Tours - Hôpital Bretonneau, Tours

37203

Tennessee Oncology, Nashville

37232

Vanderbilt University Medical Center, Nashville

44093

CHU de Nantes - Hôtel-Dieu, Nantes

55905

Mayo Clinic Cancer Center (MCCC) - Rochester, Rochester

59000

Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille

69495

Centre Hospitalier Lyon-Sud, Pierre-Bénite

72205

Duke Clinical Research Institute, Durham

75012

Hôpital Saint-Antoine, Paris

80218

Colorado Blood Cancer Institute, Denver

86021

CHU de Poitiers, Poitiers

94010

CHU Hôpital Henri Mondor, Créteil

07601

Hackensack University Medical Center, Hackensack

Unknown

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse